CTRI/2010/091/000176CompletedPhase 3
A PROSPECTIVE, PHASE III, RANDOMIZED, OPEN-LABEL, COMPARATIVE, MULTICENTRE CLINICAL TRIAL OF TIAPRIDE TO EVALUATE ITS SAFETY AND EFFICACY IN THE TREATMENT OF AGITATION AND AGGRESSIVENESS IN ADULT AND ELDERLY PATIENTS WITH COGNITIVE IMPAIRMENT
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Enrollment
- 240
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •(1) Adult and elderly patients (Age 50-90 years) of either sex*, diagnosed to be suffering from mild to moderate cognitive impairment due to dementia, with behavioral trouble in the form of agitation and/or aggressiveness, as substantiated by the Multidimensional Observational Scale for Elderly Subjects (MOSES) Irritability Subscale score ranging from 16 to 30
- •[* In case of females: either post-menopausal, surgically sterile, or using a medically accepted means of contraception with a negative serum pregnancy test result]
- •(2) Cognitively impaired cases should have the diagnosis of Alzheimer's disease, vascular dementia, or mixed dementia
- •(3) Patients or his/her legally acceptable representative is willing to provide informed consent
Exclusion Criteria
- •At least one of the items on MOSES Irritability Subscale rated 5 or no response at screening Acute psychosis Hyperprolactinemia Disease conditions augmented by increased prolactin levels Undergoing treatment with prohibited medications viz dopaminergic agonists drugs known to prolong QTc interval drugs causing bradycardia drugs causing electrolyte imbalance and certain psychotropic medications Clinically significant cardiac disorders Clinically significant seizure disorders History of alcohol or drug abuse within six months prior to screening Impaired hepatic function Pregnancy or lactation Known hypersensitivity to benzamide or butyrophenone group of drugs or to any components in their formulation Extrapyramidal symptoms History of cerebrovascular accident within previous 3 months Any other condition that in the opinion of the investigator renders the patient inappropriate for enrollment
Investigators
Similar Trials
Terminated
Not Applicable
A Phase III, Open-Label, Prospective, Randomized, Multicenter, Neo-adjuvant study of chemotherapy versus endocrine therapy in premenopausal patient with hormone responsive, HER2 negative, lymph node positive breast cancerKCT0000460Asan Medical Center290
Completed
Phase 3
study of drug (rhoclone) on Rh negative blood group mother giving birth to Rh positive blood group babyCTRI/2015/09/006172Bharat Serums Vaccines Limited
Not yet recruiting
Phase 3
Effectiveness and Safety of a New Diabetes Medication with Conventional Treatment in Patients with Type 2 DiabetesCTRI/2024/02/062299Eris Lifesciences Ltd
Active, not recruiting
Phase 3
Phase III, Randomized, Open Label,Parallel group, Multicentric clinical studyCTRI/2022/01/039154SV Pvt Ltd
Completed
Phase 3
Phase III Randomized Open Label Parallel Multicentric clinical studyCTRI/2022/07/044440SV Pvt Ltd202